Tvardi Therapeutics, Inc. Total Assets
Tvardi Therapeutics, Inc. total assets. Based on the latest financial reports, Tvardi Therapeutics, Inc. (TVRD) holds total assets worth $17.52 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Tvardi Therapeutics, Inc. stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Tvardi Therapeutics, Inc. (2020–2025)
Total assets of Tvardi Therapeutics, Inc. from 2020 to 2025. This chart illustrates how Tvardi Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. See TVRD share price today for real-time trading data and today's change.
Tvardi Therapeutics, Inc. - Asset Composition Analysis
Tvardi Therapeutics, Inc. Total Assets Breakdown (December 2025)
Tvardi Therapeutics, Inc. total assets breakdown as of December 2025. Tvardi Therapeutics, Inc.'s total assets of $17.52 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 64.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $322.00K | 1.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Tvardi Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Tvardi Therapeutics, Inc.'s working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tvardi Therapeutics, Inc.'s current assets represent 98.3% of total assets in 2025, an increase from 71.9% in 2020.
- Cash Position: Cash and equivalents constituted 64.7% of total assets in 2025, up from 11.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 1.0% of total assets.
Tvardi Therapeutics, Inc. Competitors by Total Assets
Key competitors of Tvardi Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Tvardi Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.87 | 4.04 | 4.40 |
| Quick Ratio | 1.87 | 4.04 | 4.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.96 Million | $32.45 Million | $77.72 Million |
Tvardi Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Tvardi Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.94 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | -26.8% |
| Total Assets | $32.07 Million |
| Market Capitalization | $11.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tvardi Therapeutics, Inc.'s assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Tvardi Therapeutics, Inc.'s assets decreased by 26.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tvardi Therapeutics, Inc. (2020–2025)
The table below shows the annual total assets of Tvardi Therapeutics, Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $32.07 Million | -26.82% |
| 2024-12-31 | $43.83 Million | +62.32% |
| 2023-12-31 | $27.00 Million | -40.13% |
| 2022-12-31 | $45.10 Million | -81.75% |
| 2021-12-31 | $247.06 Million | -8.89% |
| 2020-12-31 | $271.16 Million | -- |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical d… Read more